What is Shylicine®?

Shylicine® [patent pending] is a cocktail that is developed with the ultimate goal of eliminating the need for TPN in Microvillus Inclusion Disease (MVID) patients.

Shylicine® reverses the imbalance of secretion and absorption caused by MVID and restores the appearance and the function of the intestinal mucosa. It is currently limited to investigational use only and is not available for sale.


July 25, 2018 – Hamden, Connecticut

Vanessa Research. announces launch of MVID educational website and video in Turkish language

(VRI) is pleased to announce the launch of its educational website focused on microvillus inclusion disease (MVID) translated into the Turkish language. The website explains the mechanism of MVID, provides targeted resources both for doctors and caregivers, and publishes new scientific research and other pertinent news and information related to this rare genetic disease.

Read more

June 28, 2018 – Hamden, Connecticut

New MVID educational video from Vanessa Research

Vanessa Research. (VRI), has announced the launch of a new educational video ( link ) on microvillus inclusion disease (MVID) – a rare, genetic intestinal disease that causes severe diarrhea in young babies, and it is resistant to treatment.

Read more

September 15, 2017 – Hamden, Connecticut

Shylicine™ awaits orphan designation

We have taken many steps this summer to getting Shylicine approved for use in treating microvillus inclusion disease, a rare pediatric disorder that causes chronic diarrhea. Our goal with this oral anti-diarrheal treatment is to restore intestinal function so patients can eat and drink normally.

Read more